Mirum (MIRM) | Financial Analysis & Statements
Financial Overview
Latest Annual: 2024Income Metrics
Revenue
336.9M
Gross Profit
255.2M
75.77%
Operating Income
-87.6M
-26.00%
Net Income
-87.9M
-26.10%
EPS (Diluted)
-$1.85
Balance Sheet Metrics
Total Assets
670.8M
Total Liabilities
445.1M
Shareholders Equity
225.6M
Debt to Equity
1.97
Cash Flow Metrics
Operating Cash Flow
9.8M
Free Cash Flow
-10.7M
Revenue & Profitability Trend
Mirum Income Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 336.9M | 186.4M | 77.1M | 19.1M | 0 |
| Cost of Goods Sold | 81.6M | 47.0M | 12.4M | 1.9M | 0 |
| Gross Profit | 255.2M | 139.3M | 64.7M | 17.2M | 0 |
| Operating Expenses | 342.9M | 248.5M | 195.9M | 190.6M | 104.3M |
| Operating Income | -87.6M | -109.2M | -131.2M | -173.4M | -104.3M |
| Pre-tax Income | -86.9M | -162.4M | -142.1M | -84.0M | -103.3M |
| Income Tax | 1.0M | 991.0K | -6.4M | 37.0K | 6.0K |
| Net Income | -87.9M | -163.4M | -135.7M | -84.0M | -103.3M |
| EPS (Diluted) | -$1.85 | -$4.00 | -$4.02 | -$2.77 | -$4.09 |
Income Statement Trend
Mirum Balance Sheet From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | 392.8M | 387.5M | 190.2M | 166.6M | 236.4M |
| Non-Current Assets | 278.0M | 259.1M | 162.7M | 128.1M | 4.5M |
| Total Assets | 670.8M | 646.6M | 352.9M | 294.7M | 240.9M |
| Liabilities | |||||
| Current Liabilities | 126.6M | 87.1M | 64.7M | 42.6M | 18.5M |
| Non-Current Liabilities | 318.6M | 310.9M | 146.1M | 131.8M | 50.3M |
| Total Liabilities | 445.1M | 398.0M | 210.9M | 174.4M | 68.8M |
| Equity | |||||
| Total Shareholders Equity | 225.6M | 248.7M | 142.0M | 120.2M | 172.1M |
Balance Sheet Composition
Mirum Cash Flow Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -87.9M | -163.4M | -135.7M | -84.0M | -103.3M |
| Operating Cash Flow | 9.8M | -80.1M | -113.9M | -129.3M | -87.2M |
| Investing Activities | |||||
| Capital Expenditures | -993.0K | -109.0K | -278.0K | -24.0K | -225.0K |
| Investing Cash Flow | -70.1M | -87.2M | 7.7M | 67.5M | 37.9M |
| Financing Activities | |||||
| Dividends Paid | - | - | - | 0 | - |
| Financing Cash Flow | 0 | 326.1M | 101.8M | 71.4M | 181.3M |
| Free Cash Flow | -10.7M | -91.1M | -120.4M | -151.8M | -89.3M |
Cash Flow Trend
Mirum Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
-28.62
Forward P/E
-57.23
Price to Book
10.56
Price to Sales
6.50
PEG Ratio
-57.23
Profitability Ratios
Profit Margin
-20.39%
Operating Margin
-13.61%
Return on Equity
-33.06%
Return on Assets
-7.11%
Financial Health
Current Ratio
3.22
Debt to Equity
135.97
Beta
0.95
Per Share Data
EPS (TTM)
-$1.61
Book Value per Share
$4.72
Revenue per Share
$7.90
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| mirm | 2.5B | -28.62 | 10.56 | -33.06% | -20.39% | 135.97 |
| Vertex | 124.2B | 32.82 | 7.53 | -5.64% | -8.91% | 10.00 |
| Regeneron | 59.1B | 13.92 | 1.97 | 15.96% | 31.94% | 9.20 |
| Blueprint Medicines | 8.3B | -120.14 | 24.23 | -47.71% | -27.70% | 208.50 |
| Roivant Sciences | 7.4B | 1.95 | 1.61 | -12.54% | 96.86% | 1.93 |
| Bio-Techne | 7.9B | 60.87 | 3.92 | 6.53% | 10.89% | 20.99 |
Financial data is updated regularly. All figures are in the company's reporting currency.